Mylan Labs to acquire King Pharmaceuticals; deal cancelled
Mylan Laboratories Inc. has agreed to acquire King Pharmaceuticals for about $4.2bn. Under terms of the stock swap, King shareholders receive 0.9 Mylan common shares for each King common held. Based on Mylan's average share price prior to announcement, it paid $17.33 per King share, a 65% premium to market.
- Full Acquisition
- Includes Contract
- Payment Includes Stock
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com